Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial
Breast, Volume 21, No. 1, Year 2012
Notification
URL copied to clipboard!
Description
The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC). Patients were randomized to either letrozole alone (arm A, n=31) or letrozole plus trastuzumab (arm B, n=26) as first-line treatment. Additional 35 patients with HER2 negative and HR positive tumors received letrozole alone (arm C).Median time to progression in arm A was 3.3 months compared to 14.1 months in arm B (hazard ratio 0.67; p=0.23) and 15.2 months in arm C (hazard ratio 0.71; p=0.03). Clinical benefit rate was 39% for arm A compared to 65% in arm B (odds ratio 2.99, 95% CI 1.01-8.84) and 77% in arm C (odds ratio 5.34, 95% CI 1.83-15.58).The eLEcTRA trial showed that the combination of letrozole and trastuzumab is a safe and effective treatment option for patients with HER2 positive and HR positive MBC. © 2011 Elsevier Ltd.
Authors & Co-Authors
Huober, Jens
Switzerland, St Gallen
Breast Center
Germany, Tubingen
Eberhard Karls Universität Tübingen
Fasching, Peter Andreas
Germany, Erlangen
Friedrich-alexander-universität Erlangen-nürnberg
United States, Los Angeles
David Geffen School of Medicine at Ucla
Barsoum, Mohsen Samy
Egypt, Giza
Cairo University
Petruželka, Lubos B.
Czech Republic, Prague
Všeobecná Fakultní Nemocnice V Praze
Wallwiener, Diethelm R.
Germany, Tubingen
Eberhard Karls Universität Tübingen
Thomssen, C.
Germany, Halle
Martin-luther-universität Halle-wittenberg
Reimer, T.
Germany, Rostock
Universität Rostock
Paepke, Stefan
Germany, Munich
Klinikum Rechts Der Isar
Azim, Hatem A.
Egypt, Cairo
Faculty of Medicine
Ragosch, V.
Germany, Hamburg
Asklepios Klinik Altona
Kubista, E.
Austria, Vienna
Medizinische Universität Wien
Baumgärtner, A. K.
Germany, Munich
Klinikum Rechts Der Isar
Beckmann, Matthias Wilhelm
Germany, Erlangen
Friedrich-alexander-universität Erlangen-nürnberg
May, C.
Germany, Nurnberg
Novartis Pharma Gmbh bu Oncology
Nimmrich, I.
Germany, Nurnberg
Novartis Pharma Gmbh bu Oncology
Harbeck, Nadia
Germany, Koln
Universität zu Köln
Germany, Munich
Klinikum Rechts Der Isar
Statistics
Citations: 213
Authors: 16
Affiliations: 14
Identifiers
Doi:
10.1016/j.breast.2011.07.006
ISSN:
09609776
Research Areas
Cancer
Environmental
Study Design
Case-Control Study